NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

NCT07502118 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Relapsed/Refractory Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
High-grade B-cell Lymphoma (HGBCL)
Follicular Lymphoma ( FL)

Interventions

BIOLOGICAL: Talikabtagene Autoleucel

Sponsor

Health Institutes of Turkey